Artelo Biosciences, Inc. is a development stage company, which engages in discovering, licensing, developing and commercializing treatments that modulate the endocannabinoid system. The company was founded by James Manley on May 2, 2011 and is headquartered in San Diego, CA.

Overall MarketRank^™

1.57 out of 5 stars

Medical Sector

428th out of 2,043 stocks

Pharmaceutical Preparations Industry

200th out of 771 stocks

3.5 Analyst's Opinion

Consensus Rating
Artelo Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $7.00, Artelo Biosciences has a forecasted upside of 438.5% from its current price of $1.30.
Amount of Analyst Coverage
Artelo Biosciences has only been the subject of 1 research reports in the past 90 days.

2.7 Community Rank

Outperform Votes
Artelo Biosciences has received 25 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Artelo Biosciences has received 21 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Artelo Biosciences has received 54.35% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Artelo Biosciences and other stocks. Vote “Outperform” if you believe ARTL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ARTL will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Artelo Biosciences does not currently pay a dividend.
Dividend Growth
Artelo Biosciences does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Artelo Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $9,775.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 3.36% of the stock of Artelo Biosciences is held by insiders.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Artelo Biosciences is -1.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Artelo Biosciences is -1.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Artelo Biosciences has a P/B Ratio of 1.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Artelo Biosciences (NASDAQ:ARTL) Frequently Asked Questions

Is Artelo Biosciences a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Artelo Biosciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Artelo Biosciences stock.
View analyst ratings for Artelo Biosciences or view top-rated stocks.

What stocks does MarketBeat like better than Artelo Biosciences?

Wall Street analysts have given Artelo Biosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Artelo Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Artelo Biosciences' next earnings date?

Artelo Biosciences is scheduled to release its next quarterly earnings announcement on Monday, July 12th 2021.
View our earnings forecast for Artelo Biosciences.

How were Artelo Biosciences' earnings last quarter?

Artelo Biosciences, Inc. (NASDAQ:ARTL) posted its earnings results on Monday, April, 12th. The company reported ($0.03) EPS for the quarter, topping the Zacks' consensus estimate of ($0.12) by $0.09.
View Artelo Biosciences' earnings history.

How has Artelo Biosciences' stock been impacted by Coronavirus (COVID-19)?

Artelo Biosciences' stock was trading at $1.01 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ARTL shares have increased by 28.7% and is now trading at $1.30.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for ARTL?

2 brokers have issued 12 month price targets for Artelo Biosciences' stock. Their forecasts range from $7.00 to $7.00. On average, they anticipate Artelo Biosciences' share price to reach $7.00 in the next twelve months. This suggests a possible upside of 438.5% from the stock's current price.
View analysts' price targets for Artelo Biosciences or view top-rated stocks among Wall Street analysts.

Who are Artelo Biosciences' key executives?

Artelo Biosciences' management team includes the following people:

Gregory D. Gorgas, President, CEO, CFO, Secretary & Treasurer
Randy Schreckhise, Vice President-Finance & Operations
Steven D. Reich, Chief Medical Officer
Andy Yates, Chief Scientific Officer & Senior Vice President
Peter O’Brien, Senior Vice President-European Operations

Who are some of Artelo Biosciences' key competitors?

Some companies that are related to Artelo Biosciences include Processa Pharmaceuticals (PCSA), SELLAS Life Sciences Group (SLS), Aptevo Therapeutics (APVO), ASLAN Pharmaceuticals (ASLN), PDS Biotechnology (PDSB), Corvus Pharmaceuticals (CRVS), American BriVision (Holding) (ABVC), Orgenesis (ORGS), Evofem Biosciences (EVFM), Aytu Biopharma (AYTU), Cocrystal Pharma (COCP), LifeVantage (LFVN), BetterLife Pharma (PVOTF), Minerva Neurosciences (NERV) and Aileron Therapeutics (ALRN).
View all of ARTL's competitors.

What other stocks do shareholders of Artelo Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Artelo Biosciences investors own include NVIDIA (NVDA), VBI Vaccines (VBIV), Provention Bio (PRVB), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Flexion Therapeutics (FLXN), OPKO Health (OPK), Overstock.com (OSTK), Allena Pharmaceuticals (ALNA) and Advanced Micro Devices (AMD).

What is Artelo Biosciences' stock symbol?

Artelo Biosciences trades on the NASDAQ under the ticker symbol "ARTL."

Who are Artelo Biosciences' major shareholders?

Artelo Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include LVM Capital Management Ltd. MI (0.13%). Company insiders that own Artelo Biosciences stock include Connie Matsui and Gregory D Gorgas.
View institutional ownership trends for Artelo Biosciences.

Which major investors are buying Artelo Biosciences stock?

ARTL stock was purchased by a variety of institutional investors in the last quarter, including LVM Capital Management Ltd. MI. Company insiders that have bought Artelo Biosciences stock in the last two years include Connie Matsui, and Gregory D Gorgas.
View insider buying and selling activity for Artelo Biosciences or or view top insider-buying stocks.

How do I buy shares of Artelo Biosciences?

Shares of ARTL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Artelo Biosciences' stock price today?

One share of ARTL stock can currently be purchased for approximately $1.30.

How much money does Artelo Biosciences make?

Artelo Biosciences has a market capitalization of $30.07 million.

How many employees does Artelo Biosciences have?

Artelo Biosciences employs 3 workers across the globe.

What is Artelo Biosciences' official website?

The official website for Artelo Biosciences is www.artelobio.com.

Where are Artelo Biosciences' headquarters?

Artelo Biosciences is headquartered at 888 Prospect Street Suite 210, La Jolla CA, 92037.

How can I contact Artelo Biosciences?

Artelo Biosciences' mailing address is 888 Prospect Street Suite 210, La Jolla CA, 92037. The company can be reached via phone at (760) 943-1689 or via email at [email protected]

This page was last updated on 5/6/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Artelo Biosciences Stock Forecast, Price & News

Adding

Adding

Adding Artelo Biosciences, Inc.

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Headlines

About Artelo Biosciences

MarketRank™

Overall MarketRank™